🇺🇸 FDA
Patent

US 9446037

Methods for the treatment of parkinson's disease psychosis using pimavanserin

granted A61KA61K31/12A61K31/13

Quick answer

US patent 9446037 (Methods for the treatment of parkinson's disease psychosis using pimavanserin) held by ACADIA Pharmaceuticals Inc. expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/12, A61K31/13, A61K31/137, A61K31/165